LPTX Stock Overview
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Leap Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.19 |
| 52 Week High | US$10.20 |
| 52 Week Low | US$1.24 |
| Beta | 0.59 |
| 1 Month Change | 26.09% |
| 3 Month Change | -5.06% |
| 1 Year Change | -17.97% |
| 3 Year Change | -80.31% |
| 5 Year Change | -80.31% |
| Change since IPO | -95.94% |
Recent News & Updates
Recent updates
Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Deliver On Growth Plans?
Mar 13
Will Leap Therapeutics (NASDAQ:LPTX) Spend Its Cash Wisely?
Nov 22Leap Therapeutics GAAP EPS of -$0.15 misses by $0.05
Aug 12Leap Therapeutics begins trials of DKN-01 in gastric/colorectal cancers
Jul 12Leap Therapeutics: 2 Catalysts With Cancer Drug DKN-01 In The 2nd Half Of 2022
Jun 27Here's Why We're Watching Leap Therapeutics' (NASDAQ:LPTX) Cash Burn Situation
May 01Leap Therapeutics: Waiting For One More Leap
Feb 18We're Hopeful That Leap Therapeutics (NASDAQ:LPTX) Will Use Its Cash Wisely
Jan 04Leap Therapeutics: What Prompted Prioritizing This Precision Oncology Company?
Nov 29Leap Therapeutics: All On The Line
Oct 13Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?
Sep 15Is Leap Therapeutics (NASDAQ:LPTX) In A Good Position To Invest In Growth?
Jun 01Companies Like Leap Therapeutics (NASDAQ:LPTX) Are In A Position To Invest In Growth
Mar 03Could The Leap Therapeutics, Inc. (NASDAQ:LPTX) Ownership Structure Tell Us Something Useful?
Jan 27
Announcing: Leap Therapeutics (NASDAQ:LPTX) Stock Increased An Energizing 127% In The Last Year
Dec 23Need To Know: Analysts Are Much More Bullish On Leap Therapeutics, Inc. (NASDAQ:LPTX)
Nov 18Shareholder Returns
| LPTX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -1.8% | 4.7% | 0.7% |
| 1Y | -18.0% | 2.7% | 23.9% |
Return vs Industry: LPTX underperformed the US Biotechs industry which returned 2.9% over the past year.
Return vs Market: LPTX underperformed the US Market which returned 24.2% over the past year.
Price Volatility
| LPTX volatility | |
|---|---|
| LPTX Average Weekly Movement | 14.6% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LPTX's share price has been volatile over the past 3 months.
Volatility Over Time: LPTX's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 54 | Doug Onsi | www.leaptx.com |
Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501. Leap Therapeutics, Inc. has an option and license agreement with NovaRock, Adimab, and BeiGene, Ltd.
Leap Therapeutics, Inc. Fundamentals Summary
| LPTX fundamental statistics | |
|---|---|
| Market cap | US$121.30m |
| Earnings (TTM) | -US$81.41m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.5x
P/E RatioIs LPTX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LPTX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$81.41m |
| Earnings | -US$81.41m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.13 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did LPTX perform over the long term?
See historical performance and comparison